Physician profile
Ranjan Chanda
NPI 1578677274
$1,033.51
in general payments reported to CMS, 2019-2025
14 companies · $11.77 in 2025
The $11.77 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $276 · 2021: $78.57 · 2022: $215 · 2023: $21.93 · 2024: $74.08 · 2025: $11.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $60.99 · Food and Beverage: $46.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $60.99 |
| Food and Beverage | $46.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $302.39 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $147.03 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $125.39 | 2019-2020 | |
| Akebia Therapeutics INC | $124.35 | 2020-2024 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $69.79 | 2019-2020 | |
| Nxstage Medical, INC. | $66.36 | 2019 | |
| Amgen INC. | $48.62 | 2019-2020 | |
| Vifor Pharma, INC. | $38.72 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $24.86 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $21.93 | 2023 | Xarelto |
| Mallinckrodt Enterprises LLC | $19.99 | 2019 | |
| Daiichi Sankyo INC. | $19.64 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.67 | 2019 | |
| Travere Therapeutics, INC. | $11.77 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjan Chanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.